(EMAILWIRE.COM, November 14, 2018 ) Biologics are increasingly being used in the treatment of dermatological diseases. Biologics are medications made from human or animal proteins. They are specifically designed to inhibit only a specific target portion of the immune system with fewer side effects. Biologics have been proved to be effective in the treatment of skin diseases such as psoriasis, urticaria, melanoma, blistering and granulomatous diseases. For example, Ustekinumab (Stelara), a Janssen Biotech brand, is a human monoclonal antibody used for the treatment of plaque psoriasis in the USA, Canada and Europe. New dermatology products focus on Janus Kinase (JAK) inhibitor, microgen-activated protein kinase (MEK) inhibitors and monoclonal antibodies. Some of the new biologics products include Ivermectin for the treatment of rosacea, Dupilumab for atopic dermatitis, and Etanercept (Enbrel), Adalimubab (Humira), Infliximab (Remicade) and Secukinumab (Cosentyx) for the treatment of psoriasis.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL DERMATOLOGY DRUGS MARKET TO GROW TO $42 BILLION BY 2021
North America was the largest region in the dermatology drugs market in 2017, accounting for less than one-third of the market share. This can be attributed to large number of affluent patients and generous reimbursement within the US pharma market.
Order the report at: http://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report-2018
The chart below shows the year-on-year growth of the global dermatology drugs market during 2017 2021
According to The Business Research Companys Consultant, Nitin Gianchandani, the dermatology drugs market has witnessed multiple strategic initiatives in the recent years. Top companies in the dermatology drugs market strategically acquired start-ups and mid-sized companies to broaden products and services. For instance, LEO Pharma, a Denmark-based company acquired the global dermatology business of Astellas Pharma for $725 million. This deal allows LEO to increase its product portfolio with Astellas Pharmas dermatology products including Protopic, Locoid, Locobase and Zineryt. Also Piramal Enterprises Ltd, an Indian based company acquired over-the-counter dermatology brand Caladryl in India from Valeant Pharmaceuticals Inc. Through this acquisition Piramal widened its consumer products portfolio in the skin care segment.
Download a sample of the report at: http://www.thebusinessresearchcompany.com/sample.aspx?id=272&type=smp
Johnson & Johnson was the largest competitor in the market with 11.9% of the market, generating revenues of $3.9 billion for the financial year 2016. Johnson & Johnson aims to grow its geographic footprint and increase investments in emerging markets and developed markets such as Japan. In 2016, the company spent $9.1 billion in R&D. With prioritized investments in internal R&D, strategic licensing arrangements, partnerships and select acquisitions, the company intends to build a robust product pipeline for long-term. In July 2016, J&J acquired a Japanese beauty brand Dr. Ci:Labo to strengthen its skin care business.
The dermatology drugs market includes medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.
Dermatology Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company.
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company’s management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: http://in.linkedin.com/company/the-business-research-company
Marketing TBRC
+91 8897263534
Marketing@tbrc.info
Source: EmailWire.Com 
